Difference between revisions of "Team:San Andres/Design"
| Line 1: | Line 1: | ||
<html> | <html> | ||
<head> | <head> | ||
| − | <title>wiki</title> | + | <title><endnote><head> |
| − | + | <title><endnote><head> | |
| + | <meta> | ||
| + | <title></title> | ||
| + | </head> | ||
| + | <body> | ||
| + | <title>wiki</title> | ||
| + | <meta http-equiv="Content-Type" | ||
content="text/html; charset=utf-8"> | content="text/html; charset=utf-8"> | ||
| − | + | <meta name="generator" | |
content="Google Web Designer 1.3.2.0521"> | content="Google Web Designer 1.3.2.0521"> | ||
| − | + | <style type="text/css"> | |
html, body { | html, body { | ||
width: 100%; | width: 100%; | ||
| Line 18: | Line 24: | ||
background-color: rgb(198, 169, 117); | background-color: rgb(198, 169, 117); | ||
} | } | ||
| − | + | </style> | |
| − | + | ||
| − | + | ||
<meta http-equiv="content-type" | <meta http-equiv="content-type" | ||
content="text/html; charset=ISO-8859-1"> | content="text/html; charset=ISO-8859-1"> | ||
| Line 620: | Line 624: | ||
-webkit-transform-style: preserve-3d; | -webkit-transform-style: preserve-3d; | ||
} | } | ||
| − | </style><!--navigation menu --> | + | </style><!--navigation menu --><br> |
| − | <br> | + | |
<table style="width: 968px; height: 34px;" | <table style="width: 968px; height: 34px;" | ||
class="gwd-table-nb4m editable"> | class="gwd-table-nb4m editable"> | ||
| Line 661: | Line 664: | ||
<a href="https://2015.igem.org/Team:San_Andres/Modeling" | <a href="https://2015.igem.org/Team:San_Andres/Modeling" | ||
style="color: rgb(0, 0, 0);"> Modeling</a> | style="color: rgb(0, 0, 0);"> Modeling</a> | ||
| + | </td> | ||
| + | <td style="border: 2px solid black;" | ||
| + | onmouseover="this.bgColor='#ffba00'" | ||
| + | onmouseout="this.bgColor='#FFA600'" align="center" | ||
| + | bgcolor="#ffa600" height="30"><a | ||
| + | href="https://2015.igem.org/Team:San_Andres/Results" | ||
| + | style="color: rgb(0, 0, 0);"> Results</a> | ||
</td> | </td> | ||
</tr> | </tr> | ||
| Line 673: | Line 683: | ||
<td style="border: 2px solid black;" | <td style="border: 2px solid black;" | ||
onmouseover="this.bgColor='#FFBA00'" | onmouseover="this.bgColor='#FFBA00'" | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
onmouseout="this.bgColor='#FFA600'" align="center" | onmouseout="this.bgColor='#FFA600'" align="center" | ||
bgcolor="#ffa600" height="30"> | bgcolor="#ffa600" height="30"> | ||
<a href="https://2015.igem.org/Team:San_Andres/Notebook" | <a href="https://2015.igem.org/Team:San_Andres/Notebook" | ||
| − | style="color: rgb(0, 0, 0);"> Notebook</a> | + | style="color: rgb(0, 0, 0);">Notebook</a> |
</td> | </td> | ||
<td style="border: 2px solid black;" | <td style="border: 2px solid black;" | ||
| Line 698: | Line 701: | ||
<a href="https://2015.igem.org/Team:San_Andres/Design" | <a href="https://2015.igem.org/Team:San_Andres/Design" | ||
style="color: rgb(0, 0, 0);"> Future Projections</a> | style="color: rgb(0, 0, 0);"> Future Projections</a> | ||
| + | </td> | ||
| + | <td style="border: 2px solid black;" | ||
| + | onmouseover="this.bgColor='#ffba00'" | ||
| + | onmouseout="this.bgColor='#FFA600'" align="center" | ||
| + | bgcolor="#ffa600" height="30"> | ||
| + | <a href="https://2015.igem.org/Team:San_Andres/Attributions" | ||
| + | style="color: rgb(0, 0, 0);"> Attributions</a> | ||
</td> | </td> | ||
<td style="border: 2px solid black;" | <td style="border: 2px solid black;" | ||
Revision as of 14:56, 12 September 2015
| Home | Team | Project | Parts | Modeling | Results |
| Notebook | Human Practices | Future Projections | Attributions | Collaborations |
Future Projections
If our results are the expected our future projections are the following:- Disclosure to the scientific community.
- Realize workshops in academic institutions of this enteropathy with the aim of being more known in society.
- Generate the product and market it for therapeutic purposes.
Business Model
If all goes
well, we going to patenting our pill, which give us licenses which we
can sell to pharmacies and laboratories to produce the medication and
sell it to celiac patients. This would mean a social benefit and an
benefict for us.
